Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases.
The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types.
The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors.
In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus.
The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression.
It has a license agreement with Caris Life Sciences.
Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 5, 24 | -1.07 Decreased by -189.19% | -0.88 Decreased by -21.59% |
| May 9, 24 | -1.11 Decreased by -8.82% | -0.79 Decreased by -40.51% |
| Feb 27, 24 | -0.31 Decreased by -55.00% | -0.09 Decreased by -244.44% |
| Nov 7, 23 | -0.40 Increased by +27.27% | -0.73 Increased by +45.21% |
| Aug 3, 23 | -0.37 Increased by +35.09% | -0.80 Increased by +53.75% |
| May 8, 23 | -1.02 Decreased by -361.54% | -0.66 Decreased by -54.55% |
| Feb 23, 23 | -0.20 Decreased by -116.53% | -0.79 Increased by +74.68% |
| Nov 7, 22 | -0.55 Increased by +20.29% | -0.68 Increased by +19.12% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 10.71 M Decreased by -81.90% | -45.14 M Decreased by -86.01% | Decreased by -421.50% Decreased by -927.56% |
| Jun 30, 24 | 16.96 M Decreased by -62.74% | -65.96 M Decreased by -200.46% | Decreased by -388.93% Decreased by -706.48% |
| Mar 31, 24 | 12.80 M Decreased by -32.47% | -68.03 M Decreased by -13.55% | Decreased by -531.30% Decreased by -68.14% |
| Dec 31, 23 | 44.69 M Increased by +106.80% | -19.10 M Decreased by -58.61% | Decreased by -42.74% Increased by +23.30% |
| Sep 30, 23 | 59.16 M Increased by +116.73% | -24.27 M Increased by +25.92% | Decreased by -41.02% Increased by +65.82% |
| Jun 30, 23 | 45.52 M Increased by +50.86% | -21.95 M Increased by +45.05% | Decreased by -48.23% Increased by +63.57% |
| Mar 31, 23 | 18.96 M Decreased by -77.82% | -59.92 M Decreased by -353.95% | Decreased by -315.98% Decreased by -1.24 K% |
| Dec 31, 22 | 21.61 M Decreased by -85.97% | -12.04 M Decreased by -116.48% | Decreased by -55.72% Decreased by -217.47% |